CD153 Protein (CD30L, TNFSF8 Protein)

Cluster of Differentiation 153 (Cluster of Differentiation 30L, Tumor Necrosis Factor ligand Superfamily, member 8 )

CD153 Products

CD153 Protein, Recombinant

Molecule	Species	Description	Cat. No
CD153/CD30L/TNFSF8	Human	CD153/CD30L/TNFSF8/Fc Protien, Recombinant	10040-H01H

  10040-H01H:  Immobilized recombinant human CD30L at 20 µg/ml (100 µl/well) can bind biotinylated human CD30 with a linear range of 0.31-20 ng/ml. Measured by its binding ability in a functional ELISA.

CD153 cDNA Clone

Molecule	Species	Description	Cat. No
CD153/CD30L/TNFSF8	Human	Homo sapiens CD153/CD30L/TNFSF8 cDNA Clone(NM_001244.2)	HG10040-M
CD153/CD30L/TNFSF8	Rat	Rat CD153/CD30L/TNFSF8 cDNA Clone	RG80148-G
CD153/CD30L/TNFSF8	Cynomolgus	Cynomolgus monkey TNFSF8 cDNA Clone / ORF Clone	KG90091-G

CD153 Alternative Names

CD153, CD30L, TNFSF8, CD30LG, MGC138144

CD153 Related Areas

Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>CD153/CD30L/TNFSF8

Immunology>>Innate Immunity>>Natural Killer Cell (NK Cell)>>CD153/CD30L/TNFSF8

Immunology>>Cytokine & Receptor>>TNF Superfamily>>CD153/CD30L/TNFSF8

Immunology>>Cluster of Differentiation>>Monocyte/Macrophage CD Antigen>>Other>>CD153/CD30L/TNFSF8

Immunology>>Cluster of Differentiation>>Natural Killer (NK) Cell CD Antigen>>CD153/CD30L/TNFSF8

Immunology>>Cluster of Differentiation>>T Cell CD Antigen>>Helper T Cells>>CD153/CD30L/TNFSF8

CD153 Background

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

CD153 Related Studies

1. Hargreaves PG, et al. (2002) Soluble CD30 binds to CD153 with high affinity and blocks transmembrane signaling by CD30. Eur J Immunol. 32(1): 163-73.
2. Blazar BR, et al. (2004) CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 173(5): 2933-41.
3. Oflazoglu E, et al. (2009) Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol. 647: 174-85.